Loading...
Loading...
Also known as: CJC-1295 DAC, Drug Affinity Complex CJC
Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.
Benefits
6
Conditions
5
Evidence
Clinical trials, pharmacokinetic studies+ studies
Source
Synthetic GHRH analog with drug affinity complex
Gabriel Brain Score
Moderate
Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.
GHRH analog with DAC modification binding to albumin for extended half-life (6-8 days), provides sustained GH and IGF-1 elevation, mimics continuous GHRH stimulation rather than pulsatile.
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Clinical trials, pharmacokinetic studies
Clinical evidence for sustained GH and IGF-1 elevation. Provides continuous rather than pulsatile GH release, which may be less physiologic than modified GRF (CJC-1295 no DAC).
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Potent hexapeptide ghrelin mimetic with strong GH-releasing effects and cardioprotective properties.
Long-acting GHRH analog that stimulates sustained growth hormone release.